Celgene Pays $2.9B For Abraxis – Emii.com
By Dr. Matthew Watson
 The Star-Ledger - NJ.com | Celgene Pays $2.9B For Abraxis Emii.com Celgene has acquired biotechnology company, Abraxis BioScience, for $2.9 billion, The Wall Street Journal reports. Celgene expects the transaction to close ... Prominent Drug Chief to Sell Abraxis BioScience to Celgene for $2.9 BillionNew York Times AP Business NewsBrief at 7:19 am EDTTMCnet A Billionaire's Biotech Deal And Old Drugs RebornForbes (blog) Financial Times -DailyFinance -Trading Markets (press release) all 665 news articles » |
Uncategorized
Comments Off on Celgene Pays $2.9B For Abraxis – Emii.com |
July 1st, 2010
This author published 5872 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research